Ascletis Pharma, Inc. (1672) Stock Statistics & Valuation Metrics

Ascletis Pharma, Inc. has a market cap or net worth of HK$13.66B. The enterprise value is HK$6.76B.

Ascletis Pharma, Inc. has 998,250,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ascletis Pharma, Inc.’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -20.40%.

The current PE Ratio of Ascletis Pharma, Inc. is ―. Ascletis Pharma, Inc.’s PEG ratio is ―.

In the last 12 months, Ascletis Pharma, Inc. had revenue of 1.28M and earned -300.94M in profits. Earnings per share was -0.30.

In the last 12 months, operating cash flow was -203.41M and capital expenditures 0.00, giving a free cash flow of -203.41M billion.

Ascletis Pharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Ascletis Pharma, Inc. upcoming earnings date is Mar 31, 2026, TBA (Confirmed).

Ascletis Pharma, Inc. as a current ratio of 12.88, with Debt / Equity ratio of 0.39%

In the past 12 months, Ascletis Pharma, Inc. has paid 0.00 in taxes.

Ascletis Pharma, Inc. EV to EBITDA ratio is -5.05, with an EV/FCF ratio of 0.00.

Ascletis Pharma, Inc. has HK$1.95B in cash and marketable securities with HK$7.63M in debt, giving a net cash position of -HK$1.94B billion.

Gross margin is 57.29%, with operating margin of -31442.17%, and net profit margin of -23455.65%.

The average price target for Ascletis Pharma, Inc. is HK$23.38, which is 11.43% higher than the current price. The consensus rating is Moderate Buy